Why Glaucoma Often Goes Unnoticed Until Late
Picture someone who bumps into a doorframe more often than before, or misses a car approaching from the side. They assume they are tired or distracted. In some forms of glaucoma, that slow loss of side vision is the first thing a person notices, and by then some damage has already happened.
Glaucoma is a group of eye conditions that damage the optic nerve, the cable that carries visual information from the eye to the brain. Open-angle glaucoma, the form most often discussed in drug development, typically develops quietly, without pain.
That is why research into new treatments matters, and why the number of glaucoma clinical trials underway is worth understanding.
What the DelveInsight Pipeline Report Says
The market research firm DelveInsight tracks drugs in development in a report called Glaucoma Pipeline Insight. The 2025 edition describes more than 50 companies and more than 50 pipeline drugs in the glaucoma landscape. These are investigational therapies, not treatments you can ask your doctor for today.
The report groups candidates by development stage: Phase III (late stage), Phase II (mid stage), Phase I (early stage), and preclinical or discovery work. It also separates drugs by route of administration and by whether they are single-agent or combination products.
Note that this is a market-research assessment published by a commercial firm, not a peer-reviewed study. It is useful for seeing where research effort is going, but it does not tell you which therapies will work or be approved.
Examples of Candidates Moving Through Trials
A few named programs show the range of approaches. The 2025 report lists NCX 470, from Nicox Ophthalmics, among its late-stage Phase III products.
The same report notes that in July 2025, Glaukos Corporation ran a Phase 2/Phase 3 trial of a second-generation travoprost intracameral implant. The trial evaluated its safety and efficacy. An intracameral implant sits inside the front chamber of the eye instead of being applied as a drop.
Earlier DelveInsight material points to other approaches. The 2024 edition mentions Betaliq’s BTQ-1902 in Phase II for open-angle glaucoma, and Peregrine Ophthalmic’s POLAT 001, a liposomal latanoprost, which had completed a pilot Phase IIa trial in the US. It also lists Santen Pharmaceutical’s DE-126 in Phase III.
Those phase labels come from the 2024 report and may have changed since. Check the latest registry entry or company announcement before treating any phase as current.
How Glaucoma Is Managed Today
Treatment for open-angle glaucoma aims to lower intraocular pressure (IOP) to help prevent further optic nerve damage. Your eye doctor chooses the approach based on your type of glaucoma, your IOP, and how much damage is already present.
Diagnosis usually involves several tests rather than one:
Tonometry measures the pressure inside the eye.
Gonioscopy lets the doctor look at the drainage angle, which helps distinguish open-angle from angle-closure glaucoma.
Visual field testing maps your peripheral vision and can reveal gaps you have not noticed.
Optic nerve examination checks the nerve for the changes glaucoma causes. Imaging such as optical coherence tomography (OCT) may be used to track it over time.
Much of the pipeline work is aimed at the practical problems of current care, such as how often treatment must be taken. That is one reason implants and extended-release designs appear in the report. Whether they deliver real benefits is what the trials are meant to show.
Who Should Pay Closer Attention
Doctors typically consider several risk factors when deciding how often to screen someone. These include older age, a family history of glaucoma, and elevated eye pressure. Other eye conditions or past eye injuries can also be relevant.
If any of these apply to you, regular comprehensive eye exams are the most reliable way to catch changes early. A normal pressure reading on one visit does not rule out glaucoma, which is why the other tests are part of the exam.
When to See a Doctor
Book a routine eye exam if you have risk factors, have never had a dilated exam, or have noticed any gradual narrowing of your side vision. Do not wait for pain, because many people with open-angle glaucoma have none.
Seek urgent care right away for sudden, severe eye pain, especially with headache, nausea or vomiting, blurred vision, a red eye, or halos around lights. These symptoms may indicate acute angle-closure glaucoma, which is a medical emergency.
Common Questions About Glaucoma Clinical Trials
Does a large pipeline mean new treatments are coming soon?
Not necessarily. Many candidates in a pipeline are early-stage, and many drugs do not reach approval. The figure of 50+ companies shows the amount of activity, not guaranteed results.
Can I join a clinical trial?
Possibly, depending on your diagnosis and the trial’s eligibility rules. Ask your ophthalmologist, and look up trials in a public registry such as ClinicalTrials.gov. Join only through an official listing, and talk through risks and benefits with your doctor first.
Should I change my current treatment because of this research?
No. Do not stop or alter prescribed treatment based on pipeline news. Any change should come from your eye doctor after a proper evaluation.
Your Next Step
If it has been more than a year or two since your last comprehensive eye exam, or you have a family history of glaucoma, schedule one. Write down your IOP readings and any visual field results so you can compare them from visit to visit. Then ask your eye doctor which monitoring schedule fits your risk.
